Multiple sclerosis (MS) is an immune-mediated inflammatory disease characterized by demyelination and degeneration in the ...

Vaccination against COVID-19 is crucial for individuals with multiple sclerosis (MS), ensuring safety and effectiveness despite immunosuppressive therapies.

Researchers at the Karolinska Institute in Sweden have identified 18 new potential drug targets for treating multiple ...

A study led by Cambridge researchers has shed light on how neural stem cell grafts could help restore myelin in the central ...

A study led by Cambridge researchers has shed light on how neural stem cell grafts could help restore myelin in the central ...

Background Extended interval dosing (EID) of natalizumab is a promising strategy to optimise treatment in multiple sclerosis (MS). Personalised EID by therapeutic drug monitoring can enable further ...

Relapsing Multiple Sclerosis: Navigating Treatment Conundrums This activity is supported by an educational grant from Novartis Pharmaceuticals, Inc.

Barclays analyst Emily Field lowered the firm’s price target on Sanofi (SNY) to EUR 115 from EUR 125 and keeps an Overweight rating on the shares.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Sanofi’s Sarclisa (isatuximab) has been recommended by the European Medicines Agency’s human medicines committee as part of a combination treatment for newly diagnosed multiple myeloma (MM). The ...

No writing assistance was utilized in the production of this drug profile manuscript. Cite this: FTY720 (Fingolimod) for Relapsing Multiple Sclerosis - Medscape - May 01, 2008.